

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

1. PRODUCT AND COMPANY IDENTIFICATION

Product name : Gentamicin / Posaconazole / Mometasone Suspension Formulation

Product code : Mometamax Single

Other means of identification : Mometamax Ultra Ear Drops Suspension for Dogs (91464)

Manufacturer or supplier's details

Company : MSD

Address : 126 E. Lincoln Avenue
Rahway, New Jersey U.S.A. 07065

Telephone : +1-908-740-4000

Emergency telephone number : +1-908-423-6000

E-mail address : EHSDATASTEWARD@msd.com

Recommended use of the chemical and restrictions on use

Recommended use : Veterinary product

Restrictions on use : Not applicable

2. HAZARDS IDENTIFICATION

GHS Classification

Reproductive toxicity : Category 1A

Short-term (acute) aquatic hazard : Category 1

Long-term (chronic) aquatic hazard : Category 2

GHS label elements

Hazard pictograms :



Signal word : Danger

Hazard statements : H360D May damage the unborn child.

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version 6.0 Revision Date: 2024/12/03 SDS Number: 1244503-00020 Date of last issue: 2023/11/20 Date of first issue: 2017/01/27

H400 Very toxic to aquatic life.
H411 Toxic to aquatic life with long lasting effects.

Precautionary statements : **Prevention:**
P201 Obtain special instructions before use.
P202 Do not handle until all safety precautions have been read and understood.
P273 Avoid release to the environment.
P280 Wear protective gloves/ protective clothing/ eye protection/ face protection.
Response:
P308 + P313 IF exposed or concerned: Get medical advice/ attention.
P391 Collect spillage.
Storage:
P405 Store locked up.
Disposal:
P501 Dispose of contents/ container to an approved waste disposal plant.

Other hazards which do not result in classification

None known.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
White mineral oil (petroleum)	8042-47-5	>= 60 -<= 100
Gentamicin	1403-66-3	>= 0.3 -< 1
Posaconazole	171228-49-2	>= 0.25 -< 1
Mometasone	83919-23-7	>= 0.025 -< 0.25

4. FIRST AID MEASURES

General advice : In the case of accident or if you feel unwell, seek medical advice immediately.
When symptoms persist or in all cases of doubt seek medical advice.

If inhaled : If inhaled, remove to fresh air.
Get medical attention.

In case of skin contact : In case of contact, immediately flush skin with soap and plenty of water.
Remove contaminated clothing and shoes.
Get medical attention.

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

	<p>Wash clothing before reuse. Thoroughly clean shoes before reuse.</p>
In case of eye contact	<p>Flush eyes with water as a precaution. Get medical attention if irritation develops and persists.</p>
If swallowed	<p>If swallowed, DO NOT induce vomiting. Get medical attention. Rinse mouth thoroughly with water.</p>
Most important symptoms and effects, both acute and delayed	<p>May damage the unborn child.</p>
Protection of first-aiders	<p>First Aid responders should pay attention to self-protection, and use the recommended personal protective equipment when the potential for exposure exists (see section 8).</p>
Notes to physician	<p>Treat symptomatically and supportively.</p>

5. FIREFIGHTING MEASURES

Suitable extinguishing media	<p>Water spray Alcohol-resistant foam Carbon dioxide (CO₂) Dry chemical</p>
Unsuitable extinguishing media	<p>None known.</p>
Specific hazards during fire-fighting	<p>Exposure to combustion products may be a hazard to health.</p>
Hazardous combustion products	<p>Carbon oxides</p>
Specific extinguishing methods	<p>Use extinguishing measures that are appropriate to local circumstances and the surrounding environment. Use water spray to cool unopened containers. Remove undamaged containers from fire area if it is safe to do so. Evacuate area.</p>
Special protective equipment for firefighters	<p>In the event of fire, wear self-contained breathing apparatus. Use personal protective equipment.</p>

6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures	<p>Use personal protective equipment. Follow safe handling advice (see section 7) and personal protective equipment recommendations (see section 8).</p>
Environmental precautions	<p>Avoid release to the environment. Prevent further leakage or spillage if safe to do so. Prevent spreading over a wide area (e.g. by containment or oil</p>

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

barriers).

Retain and dispose of contaminated wash water.

Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up

- : Soak up with inert absorbent material. For large spills, provide dyking or other appropriate containment to keep material from spreading. If dyked material can be pumped, store recovered material in appropriate container. Clean up remaining materials from spill with suitable absorbent. Local or national regulations may apply to releases and disposal of this material, as well as those materials and items employed in the cleanup of releases. You will need to determine which regulations are applicable. Sections 13 and 15 of this SDS provide information regarding certain local or national requirements.

7. HANDLING AND STORAGE

Technical measures

- : See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.

Local/Total ventilation

- : If sufficient ventilation is unavailable, use with local exhaust ventilation.

Advice on safe handling

- : Do not get on skin or clothing.
Do not breathe vapours or spray mist.
Do not swallow.
Avoid contact with eyes.
Handle in accordance with good industrial hygiene and safety practice, based on the results of the workplace exposure assessment
Keep container tightly closed.
Take care to prevent spills, waste and minimize release to the environment.

Conditions for safe storage

- : Keep in properly labelled containers.
Store locked up.
Keep tightly closed.

Store in accordance with the particular national regulations.

Materials to avoid

- : Do not store with the following product types:
Strong oxidizing agents

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type (Form of exposure)	Control parame- ters / Permissible concentration	Basis

Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

White mineral oil (petroleum)	8042-47-5	NAB (Mist)	5 mg/m ³	ID OEL
		PSD (Mist)	10 mg/m ³	ID OEL
		TWA (Inhalable particulate matter)	5 mg/m ³	ACGIH
Gentamicin	1403-66-3	TWA	0.1 mg/m ³ (OEB 2)	Internal
Further information: OTO				
Posaconazole	171228-49-2	TWA	300 µg/m ³ (OEB 2)	Internal
Mometasone	83919-23-7	TWA	1 µg/m ³ (OEB 4)	Internal
		Further information: Skin		
		Wipe limit	10 µg/100 cm ²	Internal

Engineering measures

: The information below is intended for larger pilot/commercial-scale operations and manufacturing. For smaller scale, clinical, or pharmacy settings, site-specific internal risk assessment practices should be conducted to determine appropriate exposure control measures. The health hazard risks of handling this material are dependent on multiple factors, including but not limited to physical form and quantity handled. If applicable, use process enclosures, local exhaust ventilation (e.g., Biosafety Cabinet, Ventilated Balance Enclosures), or other engineering controls to maintain airborne levels below recommended exposure limits. If exposure limits have not been established, maintain airborne levels as low as reasonably achievable.

All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment.

Essentially no open handling permitted.

Use closed processing systems or containment technologies. If handled in a laboratory, use a properly designed biosafety cabinet, fume hood, or other containment device if the potential exists for aerosolization. If this potential does not exist, handle over lined trays or benchtops.

Personal protective equipment

Respiratory protection	: If adequate local exhaust ventilation is not available or exposure assessment demonstrates exposures outside the recommended guidelines, use respiratory protection.
Filter type	: Combined particulates and organic vapour type
Hand protection	
Material	: Chemical-resistant gloves
Remarks	: Consider double gloving.
Eye protection	: Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles.

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

	<p>Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.</p>
Skin and body protection	<p>: Work uniform or laboratory coat. Additional body garments should be used based upon the task being performed (e.g., sleevelets, apron, gauntlets, disposable suits) to avoid exposed skin surfaces. Use appropriate degowning techniques to remove potentially contaminated clothing.</p>
Hygiene measures	<p>: If exposure to chemical is likely during typical use, provide eye flushing systems and safety showers close to the working place. When using do not eat, drink or smoke. Wash contaminated clothing before re-use. The effective operation of a facility should include review of engineering controls, proper personal protective equipment, appropriate degowning and decontamination procedures, industrial hygiene monitoring, medical surveillance and the use of administrative controls.</p>

9. PHYSICAL AND CHEMICAL PROPERTIES

	Appearance	: suspension
	Colour	: white to off-white
	Odour	: No data available
	Odour Threshold	: No data available
	pH	: No data available
	Melting point/freezing point	: No data available
	Initial boiling point and boiling range	: No data available
	Flash point	: No data available
	Evaporation rate	: No data available
	Flammability (solid, gas)	: Not applicable
	Flammability (liquids)	: No data available
	Upper explosion limit / Upper flammability limit	: No data available
	Lower explosion limit / Lower flammability limit	: No data available

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Vapour pressure	:	No data available
Relative vapour density	:	No data available
Relative density	:	No data available
Density	:	0.874 g/cm ³
Solubility(ies)	:	
Water solubility	:	No data available
Partition coefficient: n-octanol/water	:	Not applicable
Auto-ignition temperature	:	No data available
Decomposition temperature	:	No data available
Viscosity	:	
Viscosity, kinematic	:	No data available
Explosive properties	:	Not explosive
Oxidizing properties	:	The substance or mixture is not classified as oxidizing.
Molecular weight	:	No data available
Particle characteristics	:	
Particle size	:	Not applicable

10. STABILITY AND REACTIVITY

Reactivity	:	Not classified as a reactivity hazard.
Chemical stability	:	Stable under normal conditions.
Possibility of hazardous reactions	:	Can react with strong oxidizing agents.
Conditions to avoid	:	None known.
Incompatible materials	:	Oxidizing agents
Hazardous decomposition products	:	No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Information on likely routes of exposure	:	Inhalation Skin contact Ingestion Eye contact
--	---	--

Acute toxicity

Not classified based on available information.

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27**Components:****White mineral oil (petroleum):**

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 5 mg/l Exposure time: 4 h Test atmosphere: dust/mist Assessment: The substance or mixture has no acute inhalation toxicity
Acute dermal toxicity	: LD50 (Rabbit): > 2,000 mg/kg Assessment: The substance or mixture has no acute dermal toxicity

Gentamicin:

Acute oral toxicity	: LD50 (Rat): 8,000 - 10,000 mg/kg LD50 (Mouse): 10,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 0.2 mg/l Exposure time: 4 h Test atmosphere: dust/mist Remarks: No mortality observed at this dose.
Acute toxicity (other routes of administration)	: LD50 (Rat): 67 - 96 mg/kg Application Route: Intravenous LD50 (Rat): 371 - 384 mg/kg Application Route: Intramuscular LDLo (Monkey): 30 mg/kg Application Route: Intravenous

Posaconazole:

Acute oral toxicity	: LD50 (Rat): > 5,000 mg/kg LD50 (Mouse): > 3,000 mg/kg
Acute dermal toxicity	: LD50 (Rat): > 2,000 mg/kg

Mometasone:

Acute oral toxicity	: LD50 (Rat): > 2,000 mg/kg LD50 (Mouse): > 2,000 mg/kg
Acute inhalation toxicity	: LC50 (Rat): > 3.3 mg/l Exposure time: 4 h Test atmosphere: dust/mist

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Remarks: No mortality observed at this dose.

LC50 (Mouse): > 3.2 mg/l
Exposure time: 4 h
Test atmosphere: dust/mist

Acute toxicity (other routes of administration) : LD50 (Rat): 300 mg/kg
Application Route: Subcutaneous
Symptoms: Breathing difficulties

Skin corrosion/irritation

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species : Rabbit
Result : No skin irritation

Gentamicin:

Species : Rabbit
Result : Mild skin irritation

Posaconazole:

Species : Rabbit
Result : No skin irritation

Mometasone:

Species : Rabbit
Result : No skin irritation

Serious eye damage/eye irritation

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species : Rabbit
Result : No eye irritation

Gentamicin:

Species : Rabbit
Result : Mild eye irritation

Posaconazole:

Species : Rabbit

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27**Result** : Mild eye irritation**Mometasone:****Species** : Rabbit
Result : No eye irritation**Respiratory or skin sensitisation****Skin sensitisation**

Not classified based on available information.

Respiratory sensitisation

Not classified based on available information.

Components:**White mineral oil (petroleum):****Test Type** : Buehler Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative**Gentamicin:****Remarks** : No data available**Posaconazole:****Test Type** : Magnusson-Kligman-Test
Exposure routes : Skin contact
Species : Guinea pig
Result : negative**Mometasone:****Test Type** : Maximisation Test
Exposure routes : Dermal
Species : Guinea pig
Assessment : Does not cause skin sensitisation.
Result : negative
Remarks : The results of a test on guinea pigs showed this substance to be a weak skin sensitiser.**Germ cell mutagenicity**

Not classified based on available information.

Components:**White mineral oil (petroleum):****Genotoxicity in vitro** : Test Type: In vitro mammalian cell gene mutation test
Result: negative

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Genotoxicity in vivo:

Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intraperitoneal injection
Method: OECD Test Guideline 474
Result: negative
Remarks: Based on data from similar materials

Gentamicin:

Genotoxicity in vitro

Test Type: In vitro mammalian cell gene mutation test
Result: negative

Test Type: Chromosome aberration test in vitro
Result: equivocal

Genotoxicity in vivo

Test Type: Mammalian erythrocyte micronucleus test (in vivo cytogenetic assay)
Species: Mouse
Application Route: Intravenous injection
Result: negative

Posaconazole:

Genotoxicity in vitro

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Result: negative

Genotoxicity in vivo

Test Type: Micronucleus test
Species: Mouse
Cell type: Bone marrow
Application Route: Intravenous
Result: negative

Mometasone:

Genotoxicity in vitro

Test Type: Bacterial reverse mutation assay (AMES)
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster lung cells
Result: negative

Test Type: Chromosomal aberration
Test system: Chinese hamster ovary cells
Result: positive

Test Type: Mouse Lymphoma
Result: negative

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Genotoxicity in vivo	: Test Type: Micronucleus test Species: Mouse Application Route: Oral Result: negative
	Test Type: Chromosomal aberration Species: Rat Cell type: Bone marrow Result: negative
	Test Type: unscheduled DNA synthesis assay Species: Rat Cell type: Liver cells Result: negative
Germ cell mutagenicity - Assessment	: Weight of evidence does not support classification as a germ cell mutagen.

Carcinogenicity

Not classified based on available information.

Components:**White mineral oil (petroleum):**

Species	: Rat
Application Route	: Ingestion
Exposure time	: 24 Months
Result	: negative

Gentamicin:

Carcinogenicity - Assessment	: No data available
------------------------------	---------------------

Posaconazole:

Species	: Rat
Application Route	: oral (feed)
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

Species	: Mouse
Application Route	: Oral
Exposure time	: 2 Years
Result	: positive
Remarks	: The mechanism or mode of action is not relevant in humans.

Mometasone:

Species	: Rat
---------	-------

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Application Route	:	Inhalation
Exposure time	:	2 Years
Dose	:	0.067 mg/kg body weight
Result	:	negative
Species	:	Mouse
Application Route	:	Inhalation
Exposure time	:	19 Months
Dose	:	0.160 mg/kg body weight
Result	:	negative

Reproductive toxicity

May damage the unborn child.

Components:**White mineral oil (petroleum):**

Effects on fertility	:	Test Type: One-generation reproduction toxicity study Species: Rat Application Route: Skin contact Result: negative
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rat Application Route: Ingestion Result: negative

Gentamicin:

Effects on fertility	:	Test Type: Two-generation reproduction toxicity study Species: Rat Fertility: NOAEL: 20 mg/kg body weight Result: No significant adverse effects were reported
Effects on foetal development	:	Test Type: Embryo-foetal development Species: Rabbit Developmental Toxicity: NOAEL: 3.6 mg/kg body weight Result: No embryo-foetal toxicity
		Test Type: Embryo-foetal development Species: Rat Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 75 mg/kg body weight Result: Embryo-foetal toxicity
		Test Type: Embryo-foetal development Species: Mouse Application Route: Intraperitoneal Developmental Toxicity: LOAEL: 10 mg/kg body weight Result: foetal mortality, No malformations were observed.

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Test Type: Embryo-foetal development
Species: Rat
Application Route: Intraperitoneal
Developmental Toxicity: LOAEL: 50 mg/kg body weight
Result: foetal mortality, No malformations were observed.

Reproductive toxicity - Assessment : Positive evidence of adverse effects on development from human epidemiological studies.

Posaconazole:

Effects on fertility : Test Type: Fertility/early embryonic development
Species: Rat, male
General Toxicity - Parent: NOAEL: 180 mg/kg body weight
Symptoms: No effects on mating performance
Result: negative

Test Type: Fertility/early embryonic development
Species: Rat, female
General Toxicity - Parent: NOAEL: 45 mg/kg body weight
Symptoms: No effects on mating performance
Result: negative

Effects on foetal development : Test Type: Embryo-foetal development
Species: Rat, female
Application Route: Oral
Developmental Toxicity: LOAEL: 29 mg/kg body weight
Result: Fetotoxicity, Malformations were observed.

Test Type: Embryo-foetal development
Species: Rabbit, female
Developmental Toxicity: LOAEL: 40 mg/kg body weight
Result: Fetotoxicity

Reproductive toxicity - Assessment : Some evidence of adverse effects on development, based on animal experiments.

Mometasone:

Effects on fertility : Test Type: Fertility
Species: Rat
Application Route: Subcutaneous
Fertility: NOAEL: 0.015 mg/kg body weight
Symptoms: Reduced embryonic survival, Reduced foetal weight
Result: No effects on fertility, Effect on reproduction capacity

Effects on foetal development : Test Type: Embryo-foetal development
Species: Mouse
Application Route: Subcutaneous
Embryo-foetal toxicity: LOAEL: 0.06 mg/kg body weight

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Result: Embryotoxic effects., Teratogenicity and developmental toxicity

Test Type: Embryo-foetal development

Species: Rat

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.3 mg/kg body weight

Result: Embryo-foetal toxicity

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Dermal

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Embryo-foetal toxicity, Malformations were observed.

Test Type: Embryo-foetal development

Species: Rat

Application Route: Subcutaneous

Embryo-foetal toxicity: LOAEL: 0.15 mg/kg body weight

Result: Effects on newborn

Test Type: Embryo-foetal development

Species: Rabbit

Application Route: Oral

Embryo-foetal toxicity: LOAEL: 0.7 mg/kg body weight

Result: Embryo-foetal toxicity, Malformations were observed.

Reproductive toxicity - Assessment

: Clear evidence of adverse effects on development, based on animal experiments., Some evidence of adverse effects on sexual function and fertility, based on animal experiments.

STOT - single exposure

Not classified based on available information.

Components:**Mometasone:**

||| Remarks : Based on available data, the classification criteria are not met.

STOT - repeated exposure

Not classified based on available information.

Components:**Gentamicin:**

||| Target Organs Assessment : Kidney, inner ear
: Causes damage to organs through prolonged or repeated exposure.

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27**Posaconazole:**

Exposure routes	:	Ingestion
Target Organs	:	Adrenal gland, Bone marrow, Kidney, Liver, Reproductive organs, Nervous system
Assessment	:	Causes damage to organs through prolonged or repeated exposure.

Mometasone:

Exposure routes	:	inhalation (dust/mist/fume)
Target Organs	:	Immune system, Liver, Kidney, Skin
Assessment	:	May cause damage to organs through prolonged or repeated exposure.

Repeated dose toxicity**Components:****White mineral oil (petroleum):**

Species	:	Rat
LOAEL	:	160 mg/kg
Application Route	:	Ingestion
Exposure time	:	90 Days
Species	:	Rat
LOAEL	:	>= 1 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	4 Weeks
Method	:	OECD Test Guideline 412

Gentamicin:

Species	:	Dog
LOAEL	:	3 mg/kg
Application Route	:	Intramuscular
Exposure time	:	12 Months
Target Organs	:	Kidney
Symptoms	:	Vomiting, Salivation

Species	:	Monkey
LOAEL	:	50 mg/kg
Application Route	:	Subcutaneous
Exposure time	:	3 Weeks
Target Organs	:	Kidney, inner ear

Species	:	Monkey
LOAEL	:	6 mg/kg
Application Route	:	Intramuscular
Exposure time	:	3 Weeks
Target Organs	:	Blood, Kidney, inner ear, Liver

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Species	:	Rat
NOAEL	:	5 mg/kg
LOAEL	:	10 mg/kg
Application Route	:	Intramuscular
Exposure time	:	52 Weeks
Target Organs	:	Kidney, Blood

Species	:	Rat
NOAEL	:	12.5 mg/kg
LOAEL	:	50 mg/kg
Application Route	:	Intramuscular
Exposure time	:	13 Weeks
Target Organs	:	Kidney

Posaconazole:

Species	:	Rat, female
LOAEL	:	5 mg/kg
Application Route	:	Oral
Exposure time	:	6 Months
Target Organs	:	Adrenal gland, Lungs, Heart, Liver, spleen, Kidney, Ovary

Species	:	Dog
LOAEL	:	3 mg/kg
Application Route	:	Oral
Exposure time	:	392 Days
Target Organs	:	Lungs, Liver, Brain, small intestine, Adrenal gland, Spinal cord, lymphoid tissue

Species	:	Monkey
LOAEL	:	15 mg/kg
Application Route	:	Oral
Exposure time	:	1 Months
Target Organs	:	Bone marrow, Adrenal gland, Lymph nodes, Blood

Species	:	Dog
LOAEL	:	3 mg/kg
Application Route	:	Oral
Exposure time	:	56 Weeks
Target Organs	:	Adrenal gland, Bone marrow, Kidney, Nervous system, spleen, thymus gland, Testis, lymphoid tissue

Species	:	Monkey
LOAEL	:	180 mg/kg
Application Route	:	Oral
Exposure time	:	12 Months
Target Organs	:	Blood, Gastrointestinal tract, spleen

Species	:	Monkey
LOAEL	:	8 mg/kg
Application Route	:	Intravenous

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Exposure time	:	1 Months
Target Organs	:	Cardio-vascular system, Lungs, Adrenal gland, Blood

Mometasone:

Species	:	Rat
NOAEL	:	0.005 mg/kg
LOAEL	:	0.3 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Dog
LOAEL	:	0.5 mg/kg
Application Route	:	Oral
Exposure time	:	30 d
Target Organs	:	Lymph nodes, Liver, Adrenal gland, Skin, thymus gland

Species	:	Rat
NOAEL	:	0.00013 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, Liver, thymus gland

Species	:	Dog
NOAEL	:	0.0005 mg/l
Application Route	:	inhalation (dust/mist/fume)
Exposure time	:	90 d
Target Organs	:	Adrenal gland, Lungs, Lymph nodes, spleen, Bone marrow, Kidney, thymus gland, Liver

Aspiration toxicity

Not classified based on available information.

Components:**Mometasone:**

Not applicable

Experience with human exposure**Components:****Gentamicin:**

Ingestion	:	Target Organs: Kidney Target Organs: inner ear Symptoms: Dizziness, Vertigo, hearing loss, tinnitus, fetal deafness
-----------	---	---

Posaconazole:

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

||| Ingestion : Symptoms: Cough, Headache, Nausea, Vomiting, Fever, Liver effects, Rash, pruritis, Diarrhoea, hypertension, neutropenia, electrolyte imbalance

Mometasone:

||| Inhalation : Symptoms: allergic rhinitis, Headache, pharyngitis, upper respiratory tract infection, sinusitis, oral candidiasis, Back pain, musculoskeletal pain, immune system effects, indigestion

||| Skin contact : Symptoms: Dermatitis, Itching

Further information

Components:

Mometasone:

||| Remarks : Dermal absorption possible

12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

White mineral oil (petroleum):

||| Toxicity to fish : LC50 (Oncorhynchus mykiss (rainbow trout)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203

||| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

||| Toxicity to algae/aquatic plants : NOEC (Pseudokirchneriella subcapitata (green algae)): 100 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201

||| Toxicity to fish (Chronic toxicity) : NOEC (Oncorhynchus mykiss (rainbow trout)): 1,000 mg/l
Exposure time: 28 d

||| Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 1,000 mg/l
Exposure time: 21 d

Gentamicin:

||| Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): 86 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202

||| LC50 (Americamysis): 30 mg/l
Exposure time: 96 h

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Method: US-EPA OPPTS 850.1035

Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): 10 µg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 1.5 µg/l Exposure time: 72 h Method: OECD Test Guideline 201
	EC50 (Anabaena flos-aquae (cyanobacterium)): 4.7 µg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Anabaena flos-aquae (cyanobacterium)): 1.6 µg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 100
M-Factor (Chronic aquatic toxicity)	: 1
Toxicity to microorganisms	: EC50: 288.7 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209

Posaconazole:

Toxicity to fish	: LC50 (Oncorhynchus mykiss (rainbow trout)): > 0.95 mg/l Exposure time: 96 h Method: OECD Test Guideline 203 Remarks: No toxicity at the limit of solubility
Toxicity to daphnia and other aquatic invertebrates	: EC50 (Daphnia magna (Water flea)): 0.276 mg/l Exposure time: 48 h Method: OECD Test Guideline 202
Toxicity to algae/aquatic plants	: EC50 (Pseudokirchneriella subcapitata (green algae)): > 0.509 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
	NOEC (Pseudokirchneriella subcapitata (green algae)): 0.041 mg/l Exposure time: 72 h Method: OECD Test Guideline 201
M-Factor (Acute aquatic toxicity)	: 1

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.206 mg/l
Exposure time: 33 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.244 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

M-Factor (Chronic aquatic toxicity) : 1

Toxicity to microorganisms : EC50 (Natural microorganism): > 1,000 mg/l
Exposure time: 3 h
Test Type: Respiration inhibition
Method: OECD Test Guideline 209

Mometasone:

Toxicity to fish : LC50 (Menidia beryllina (Silverside)): 0.11 mg/l
Exposure time: 96 h
Remarks: No toxicity at the limit of solubility

LC50 (Cyprinodon variegatus (sheepshead minnow)): > 5 mg/l
Exposure time: 7 d
Remarks: No toxicity at the limit of solubility

Toxicity to daphnia and other aquatic invertebrates : EC50 (Daphnia magna (Water flea)): > 5 mg/l
Exposure time: 48 h
Method: OECD Test Guideline 202
Remarks: No toxicity at the limit of solubility

EC50 (Americamysis): > 5 mg/l
Exposure time: 96 h
Method: US-EPA OPPTS 850.1035
Remarks: No toxicity at the limit of solubility

Toxicity to algae/aquatic plants : EC50 (Pseudokirchneriella subcapitata (green algae)): > 3.2 mg/l
Exposure time: 72 h
Method: OECD Test Guideline 201
Remarks: No toxicity at the limit of solubility

Toxicity to fish (Chronic toxicity) : NOEC (Pimephales promelas (fathead minnow)): 0.00014 mg/l
Exposure time: 32 d
Method: OECD Test Guideline 210

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity) : NOEC (Daphnia magna (Water flea)): 0.34 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211
Remarks: No toxicity at the limit of solubility

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

M-Factor (Chronic aquatic toxicity)	:	100
Toxicity to microorganisms	:	EC50: > 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility
	:	NOEC: 1,000 mg/l Exposure time: 3 h Test Type: Respiration inhibition Method: OECD Test Guideline 209 Remarks: No toxicity at the limit of solubility

Persistence and degradability**Components:****White mineral oil (petroleum):**

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 31 % Exposure time: 28 d
------------------	---	---

Gentamicin:

Biodegradability	:	Result: rapidly degradable Biodegradation: 100 % Exposure time: 28 d Method: OECD Test Guideline 314
------------------	---	---

Posaconazole:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 h Method: OECD Test Guideline 314
Stability in water	:	Degradation half life (DT50): > 30 d Method: OECD Test Guideline 111

Mometasone:

Biodegradability	:	Result: Not readily biodegradable. Biodegradation: 50 % Exposure time: 28 d Method: OECD Test Guideline 314
Stability in water	:	Hydrolysis: 50 %(12 d) Method: OECD Test Guideline 111

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27**Bioaccumulative potential****Components:****Gentamicin:**

Partition coefficient: n-octanol/water : log Pow: < -2

Posaconazole:Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 20
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.15

Mometasone:Bioaccumulation : Species: Lepomis macrochirus (Bluegill sunfish)
Bioconcentration factor (BCF): 107.1
Method: OECD Test Guideline 305

Partition coefficient: n-octanol/water : log Pow: 4.68

Mobility in soil**Components:****Posaconazole:**

Distribution among environmental compartments : log Koc: 5.52

Mometasone:

Distribution among environmental compartments : log Koc: 4.02

Other adverse effects

No data available

13. DISPOSAL CONSIDERATIONS**Disposal methods**Waste from residues : Do not dispose of waste into sewer.
Dispose of in accordance with local regulations.
Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal.
If not otherwise specified: Dispose of as unused product.**14. TRANSPORT INFORMATION****International Regulations**

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

UNRTDG

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Mometasone, Gentamicin)
Class : 9
Packing group : III
Labels : 9
Environmentally hazardous : yes

IATA-DGR

UN/ID No. : UN 3082
Proper shipping name : Environmentally hazardous substance, liquid, n.o.s.
(Mometasone, Gentamicin)
Class : 9
Packing group : III
Labels : Miscellaneous
Packing instruction (cargo aircraft) : 964
Packing instruction (passenger aircraft) : 964
Environmentally hazardous : yes

IMDG-Code

UN number : UN 3082
Proper shipping name : ENVIRONMENTALLY HAZARDOUS SUBSTANCE, LIQUID, N.O.S.
(Mometasone, Gentamicin)
Class : 9
Packing group : III
Labels : 9
EmS Code : F-A, S-F
Marine pollutant : yes

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code

Not applicable for product as supplied.

Special precautions for user

The transport classification(s) provided herein are for informational purposes only, and solely based upon the properties of the unpackaged material as it is described within this Safety Data Sheet. Transportation classifications may vary by mode of transportation, package sizes, and variations in regional or country regulations.

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

15. REGULATORY INFORMATION

Safety, health and environmental regulations/legislation specific for the substance or mixture

Minister of Industry Regulation No. 23/M-IND/PER/4/2013 concerning the Revision of Minister of Industry Regulation No. 87/M-IND/PER/9/2009 concerning Globally Harmonized System of Classification and Labelling of Chemicals.

Regulation of the Minister of Health No. 472 of 1996 on the Safeguarding of Substances Hazardous to Health

Hazardous substances that must be registered : Not applicable

Government Regulation No. 74 of 2001 on the Management of Hazardous and Toxic Substances

Hazardous substances approved for use : Not applicable

Prohibited substances : Not applicable

Restricted substances : Not applicable

Regulation of the Ministry of Trade No. 7 of 2022 on Distribution and Control of Hazardous Materials

Type of hazardous materials subject to distribution and control, Annex I : Not applicable

Type of hazardous materials subject to distribution and control, Annex II : Not applicable

The components of this product are reported in the following inventories:

AICS : not determined

DSL : not determined

IECSC : not determined

16. OTHER INFORMATION

Revision Date : 2024/12/03

Further information

Sources of key data used to compile the Safety Data Sheet : Internal technical data, data from raw material SDSs, OECD eChem Portal search results and European Chemicals Agency, <http://echa.europa.eu/>

Items where changes have been made to the previous version are highlighted in the body of this document by two vertical lines.

**Gentamicin / Posaconazole / Mometasone
Suspension Formulation**Version
6.0Revision Date:
2024/12/03SDS Number:
1244503-00020Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

Date format : yyyy/mm/dd

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)

ID OEL : Indonesia. Occupational Exposure Limits

ACGIH / TWA : 8-hour, time-weighted average

ID OEL / NAB : Long term exposure limit

ID OEL / PSD : Short term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR - Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

SAFETY DATA SHEET



Gentamicin / Posaconazole / Mometasone Suspension Formulation

Version
6.0

Revision Date:
2024/12/03

SDS Number:
1244503-00020

Date of last issue: 2023/11/20
Date of first issue: 2017/01/27

ID / EN